These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

135 related articles for article (PubMed ID: 38640588)

  • 1. Discovery of novel pyridone-benzamide derivatives possessing a 1-methyl-2-benzimidazolinone moiety as potent EZH2 inhibitors for the treatment of B-cell lymphomas.
    Wu D; Zeng X; Zhao Y; Qin M; Gong P
    Bioorg Med Chem; 2024 May; 105():117725. PubMed ID: 38640588
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Discovery of IHMT-EZH2-115 as a Potent and Selective Enhancer of Zeste Homolog 2 (EZH2) Inhibitor for the Treatment of B-Cell Lymphomas.
    Zhou B; Liang X; Mei H; Qi S; Jiang Z; Wang A; Zou F; Liu Q; Liu J; Wang W; Hu C; Chen Y; Wang Z; Wang B; Wang L; Liu J; Liu Q
    J Med Chem; 2021 Oct; 64(20):15170-15188. PubMed ID: 34664960
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design, synthesis and activity evaluation of quinolinone derivatives as EZH2 inhibitors.
    Cai J; You H; Qin X; Wang Y; Li W
    Bioorg Med Chem Lett; 2024 Jun; 105():129726. PubMed ID: 38580135
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Six Years (2012-2018) of Researches on Catalytic EZH2 Inhibitors: The Boom of the 2-Pyridone Compounds.
    Fioravanti R; Stazi G; Zwergel C; Valente S; Mai A
    Chem Rec; 2018 Dec; 18(12):1818-1832. PubMed ID: 30338896
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Identification of novel EZH2 inhibitors through pharmacophore-based virtual screening and biological assays.
    Wu Y; Hu J; Ding H; Chen L; Zhang Y; Liu R; Xu P; Du D; Lu W; Liu J; Liu Y; Liu YC; Lu J; Zhang J; Yao Z; Luo C
    Bioorg Med Chem Lett; 2016 Aug; 26(15):3813-7. PubMed ID: 27289323
    [TBL] [Abstract][Full Text] [Related]  

  • 6. 2,2- dimethylbenzopyran derivatives containing pyridone structural fragments as selective dual-targeting inhibitors of HIF-1α and EZH2 for the treatment of lung cancer.
    Xu H; Zhang J; Zhuang J; Chen Y; Chen L; Wang J; Cao R; Liu F; Wang K; Zhang X; Wang L; Chen G
    Bioorg Chem; 2024 Jun; 147():107419. PubMed ID: 38703440
    [TBL] [Abstract][Full Text] [Related]  

  • 7. EZH2 W113C is a gain-of-function mutation in B-cell lymphoma enabling both PRC2 methyltransferase activation and tazemetostat resistance.
    Chu L; Tan D; Zhu M; Qu Y; Ma X; Song BL; Qi W
    J Biol Chem; 2023 Apr; 299(4):103073. PubMed ID: 36858198
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Chemically induced degradation of PRC2 complex by EZH2-Targeted PROTACs via a Ubiquitin-Proteasome pathway.
    Fu M; Wang Y; Ge M; Hu C; Xiao Y; Ma Y; Gou S
    Bioorg Med Chem Lett; 2024 Nov; 113():129968. PubMed ID: 39293534
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Selective inhibition of EZH2 by ZLD10A blocks H3K27 methylation and kills mutant lymphoma cells proliferation.
    Song X; Zhang L; Gao T; Ye T; Zhu Y; Lei Q; Feng Q; He B; Deng H; Yu L
    Biomed Pharmacother; 2016 Jul; 81():288-294. PubMed ID: 27261606
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Selective inhibition of EZH2 by ZLD1039 blocks H3K27 methylation and leads to potent anti-tumor activity in breast cancer.
    Song X; Gao T; Wang N; Feng Q; You X; Ye T; Lei Q; Zhu Y; Xiong M; Xia Y; Yang F; Shi Y; Wei Y; Zhang L; Yu L
    Sci Rep; 2016 Feb; 6():20864. PubMed ID: 26868841
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Somatic mutations at EZH2 Y641 act dominantly through a mechanism of selectively altered PRC2 catalytic activity, to increase H3K27 trimethylation.
    Yap DB; Chu J; Berg T; Schapira M; Cheng SW; Moradian A; Morin RD; Mungall AJ; Meissner B; Boyle M; Marquez VE; Marra MA; Gascoyne RD; Humphries RK; Arrowsmith CH; Morin GB; Aparicio SA
    Blood; 2011 Feb; 117(8):2451-9. PubMed ID: 21190999
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-Activity Relationship Studies for Enhancer of Zeste Homologue 2 (EZH2) and Enhancer of Zeste Homologue 1 (EZH1) Inhibitors.
    Yang X; Li F; Konze KD; Meslamani J; Ma A; Brown PJ; Zhou MM; Arrowsmith CH; Kaniskan HÜ; Vedadi M; Jin J
    J Med Chem; 2016 Aug; 59(16):7617-33. PubMed ID: 27468126
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Identification of (R)-N-((4-Methoxy-6-methyl-2-oxo-1,2-dihydropyridin-3-yl)methyl)-2-methyl-1-(1-(1-(2,2,2-trifluoroethyl)piperidin-4-yl)ethyl)-1H-indole-3-carboxamide (CPI-1205), a Potent and Selective Inhibitor of Histone Methyltransferase EZH2, Suitable for Phase I Clinical Trials for B-Cell Lymphomas.
    Vaswani RG; Gehling VS; Dakin LA; Cook AS; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Cantone N; Cummings RT; Normant E; Bellon SF; Albrecht BK; Harmange JC; Trojer P; Audia JE; Zhang Y; Justin N; Chen S; Wilson JR; Gamblin SJ
    J Med Chem; 2016 Nov; 59(21):9928-9941. PubMed ID: 27739677
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Design and synthesis of (E)-1,2-diphenylethene-based EZH2 inhibitors.
    He H; Hu X; Teng F; Liu Z; Zhang Q; Feng Z; Feng Q; Yu L
    Bioorg Med Chem Lett; 2020 Mar; 30(5):126957. PubMed ID: 31959420
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel orally bioavailable EZH1/2 dual inhibitors with greater antitumor efficacy than an EZH2 selective inhibitor.
    Honma D; Kanno O; Watanabe J; Kinoshita J; Hirasawa M; Nosaka E; Shiroishi M; Takizawa T; Yasumatsu I; Horiuchi T; Nakao A; Suzuki K; Yamasaki T; Nakajima K; Hayakawa M; Yamazaki T; Yadav AS; Adachi N
    Cancer Sci; 2017 Oct; 108(10):2069-2078. PubMed ID: 28741798
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Conformationally constrained potent inhibitors for enhancer of zeste homolog 2 (EZH2).
    Xu X; Chen J; Wang G; Zhang X; Li Q; Zhou X; Guo F; Li M
    Bioorg Med Chem Lett; 2024 Jan; 97():129558. PubMed ID: 37956762
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Tazemetostat, an EZH2 inhibitor, in relapsed or refractory B-cell non-Hodgkin lymphoma and advanced solid tumours: a first-in-human, open-label, phase 1 study.
    Italiano A; Soria JC; Toulmonde M; Michot JM; Lucchesi C; Varga A; Coindre JM; Blakemore SJ; Clawson A; Suttle B; McDonald AA; Woodruff M; Ribich S; Hedrick E; Keilhack H; Thomson B; Owa T; Copeland RA; Ho PTC; Ribrag V
    Lancet Oncol; 2018 May; 19(5):649-659. PubMed ID: 29650362
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Design and Characterization of a Pyridone-Containing EZH2 Inhibitor Phosphate Prodrug.
    Kung PP; Fan C; Gukasyan HJ; Huang B; Kephart S; Kraus M; Lee JH; Sutton SC; Yamazaki S; Zehnder L
    J Med Chem; 2021 Feb; 64(3):1725-1732. PubMed ID: 33529029
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identification of catalytic and non-catalytic activity inhibitors against PRC2-EZH2 complex through multiple high-throughput screening campaigns.
    Zhou Y; Du DH; Wang J; Cai XQ; Deng AX; Nosjean O; Boutin JA; Renard P; Yang DH; Luo C; Wang MW
    Chem Biol Drug Des; 2020 Oct; 96(4):1024-1051. PubMed ID: 32394628
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Discovery, design, and synthesis of indole-based EZH2 inhibitors.
    Gehling VS; Vaswani RG; Nasveschuk CG; Duplessis M; Iyer P; Balasubramanian S; Zhao F; Good AC; Campbell R; Lee C; Dakin LA; Cook AS; Gagnon A; Harmange JC; Audia JE; Cummings RT; Normant E; Trojer P; Albrecht BK
    Bioorg Med Chem Lett; 2015 Sep; 25(17):3644-9. PubMed ID: 26189078
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.